INFUSE Bone Graft
MEDTRONIC SOFAMOR DANEK USA, INC. · Decision date Mar 19, 2026
What did the FDA decide?
FDA records P000054/S077 as a supplement to PMA P000054, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 19, 2026.
FDA approval order statement
addition of an alternate testing facility and relocation of relevant laboratories to a new building
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Orthopedic
- Decision date
- Mar 19, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P000054/S077
- Regulatory pathway
- PMA supplement
- Applicant
- MEDTRONIC SOFAMOR DANEK USA, INC.
- Product code
- MPW
- Decision code
- OK30
- Decision date
- Mar 19, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Filler, recombinant human bone morphogenetic protein, collagen scaffold, osteoinduction.
- Applicant
- Medtronic Sofamor DANEK USA, Inc.
- Product code
- MPW
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P000054/S077 received
Application receipt date recorded by FDA.
P000054/S076 · Related supplement
INFUSE Bone Graft
P000054/S077 · FDA decision
30-Day Notice
P000054/S078 · Related supplement
Infuse Bone Graft
P000054/S075 · Related supplement
INFUSE BONE GRAFT
Timeline entries are records held by MedtechLedger for P000054. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P000054
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
INFUSE Bone GraftP000054/S076 | MEDTRONIC SOFAMOR DANEK USA, INC. | PMA supplement | Feb 24, 2026 | FDA |
Infuse Bone GraftP000054/S078 | MEDTRONIC SOFAMOR DANEK USA, INC. | PMA supplement | Jul 28, 2026 | FDA |
INFUSE BONE GRAFTP000054/S075 | MEDTRONIC SOFAMOR DANEK USA, INC. | PMA supplement | Aug 26, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Sofamor DANEK USA, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 1800 Pyramid Pl., Memphis, TN, 38132
Sources and methodology
- Original FDA record: P000054/S077
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

